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Abstract
Background: Cardiac cell transplantation is compromised by low cell retention and poor graft viability. Here, the effects of
co-injecting adipose tissue-derived stem cells (ASCs) with biopolymers on cell cardiac retention, ventricular morphometry
and performance were evaluated in a rat model of myocardial infarction (MI).
Methodology/Principal Findings: 99mTc-labeled ASCs (16106 cells) isolated from isogenic Lewis rats were injected 24 hours
post-MI using fibrin a, collagen (ASC/C), or culture medium (ASC/M) as vehicle, and cell body distribution was assessed
24 hours later by c-emission counting of harvested organs. ASC/F and ASC/C groups retained significantly more cells in the
myocardium than ASC/M (13.862.0 and 26.862.4% vs. 4.860.7%, respectively). Then, morphometric and direct cardiac
functional parameters were evaluated 4 weeks post-MI cell injection. Left ventricle (LV) perimeter and percentage of
interstitial collagen in the spare myocardium were significantly attenuated in all ASC-treated groups compared to the non-
treated (NT) and control groups (culture medium, fibrin, or collagen alone). Direct hemodynamic assessment under
pharmacological stress showed that stroke volume (SV) and left ventricle end-diastolic pressure were preserved in ASC-
treated groups regardless of the vehicle used to deliver ASCs. Stroke work (SW), a global index of cardiac function, improved
in ASC/M while it normalized when biopolymers were co-injected with ASCs. A positive correlation was observed between
cardiac ASCs retention and preservation of SV and improvement in SW post-MI under hemodynamic stress.
Conclusions: We provided direct evidence that intramyocardial injection of ASCs mitigates the negative cardiac remodeling
and preserves ventricular function post-MI in rats and these beneficial effects can be further enhanced by administrating co-
injection of ASCs with biopolymers.
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Introduction
Transplantation of stem cells represents a promising approach for
cardiac repair post-myocardial infarction (MI), but developing this
therapeutic strategy for clinical use remains a challenge. A number
of issues must be optimized, which include, but are not limited to,
transplanting the appropriate type and numbers of cells, specific
timing and route of cell delivery, developing improvements in cell
retention and survival in the cardiac tissue, and identifying the
detailed mechanisms of actions underlying the desired effects [1].
Replacement of cardiomyocytes will be required for restoring
pumping capacity following large loss of tissue post-MI. However,
this goal remains unmet and different cell types have been shown,
especially in pre-clinical studies, to potentially prevent or delay
further deterioration of cardiac function post-MI. Adipose tissue-
derived stem cells (ASCs) have been considered for autologous adult
stem cell transplantation procedures due to their abundancy, ease of
sampling [2,3,4], and similarity in appearance to bone marrow cells
(BMCs) [5,6,7], with a comparable potential to differentiate into
diverse cell lineages [3,8,9,10,11,12,13], including endothelial cells
[14,15] and cardiomyocytes [16,17]. Furthermore, recent studies
have reported beneficial outcomes after administrating ASCs to
treat myocardial infarction [18,19,20,21,22].
Given that a significant number of transplanted cells detach
from the target tissue or die, during or soon after injection
[23,24,25,26,27], diverse strategies are being intensely studied to
improve cell adhesion and survival at the time of transplantation.
In situ tissue engineering or the utilization of injectable biomaterials
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as vehicles to deliver cells directly into the target tissue may
improve cell therapy by physically entrapping the cells at the
injection site and by providing a favorable structural support for
cell survival and proliferation [28]. Indeed, the combination of
cells with biopolymers improves transplanted cell survival, induces
angiogenesis, reduces infarct expansion, and preserves cardiac
function after infarction [29,30,31,32]. We demonstrated that
injection of BMCs with fibrin 72 hours after infarction increases
transplanted cardiac cell retention by 2.5-fold suggesting that
injectable biopolymers diminish the peri-implant cell loss [32].
In the present study, we evaluated both the therapeutic
potential of ASCs for cardiac repair, and the ability of two of
the most used injectable biopolymers, fibrin and collagen, to
improve ASC cardiac retention and functional outcomes after
acute myocardial infarction.
Materials and Methods
Animal model of myocardial infarction
Experimental procedures followed the institutional guidelines
for care and use of laboratory animals and were approved by the
Institutional Review Board of the University of Sa˜o Paulo Medical
School, Brazil (#527/04). Ten-week-old female inbred Lewis rats
were given rat chow diet and water ad libitum and housed under an
alternating 12 hour/12 hour light/dark cycle. Experimental
myocardial infarction was produced by ligation of the descending
left coronary artery as previously described [33]. Briefly, a lateral
thoracotomy was performed under anesthesia and the left
coronary artery was looped by a single nylon suture (5.0) at
approximately 1 mm from its origin and gently tied. This
procedure produced a clearly demarcated area (cyanotic and
bulging) of acute ischemia corresponding to the distribution of the
left coronary artery distal to the occlusion. The chest was closed
and rats were individually caged during a 24 hour recovery
period.
Cell Isolation and ex vivo Expansion
Inguinal subcutaneous adipose tissue was collected under sterile
conditions from ten-week-old male Lewis rats and rinsed with
phosphate-buffered saline (PBS). ASCs were isolated, character-
ized and maintained in culture as previously described [34,35].
Under this experimental condition, the cells are homogeneous and
express the surface markers CD90 and CD 29 and display
adipogenic and osteogenic differentiation potential. In brief,
harvested tissue was enzymatically dissociated and centrifuged.
Pelleted cells were recovered and plated onto 10 cm culture plates.
At 24 hour intervals, cultures were washed with PBS to remove
contaminating erythrocytes and other unattached cells, and refed
with fresh medium. This process was repeated for three days.
Plating and expansion medium consisted of Dulbecco’s modified
Eagle’s medium (DMEM) low glucose with 10% Fetal Bovine
Serum (FBS) and 1% (v/v) penicillin–streptomycin (1000 UI/mL–
1000 mg/mL; GIBCO BRL, Gaithersburg). Cells were maintained
at 37uC with 5% CO2 in tissue culture dishes or flasks and fed
twice per week. Cells reached 80% confluence within 5–7 days
after the initial plating (passage 0). At 80% confluence, adherent
cells were detached with 0.05% trypsin-EDTA and re-plated at
1.06104 cells/cm2. Cultures were passaged every 3–5 days and
used for experimental procedures at passage 3 and 4.
Biopolymers isolation and preparation
The fibrin polymer was prepared by combining fibrinogen and
thrombin at the time of injection. Fibrinogen was obtained from
plasma separated from 50 ml rat whole blood and 3.8% sodium
citrate (5 ml) was added. Fibrinogen was isolated using a
cryoprecipitation technique [36] and diluted to a final concentra-
tion of 300 mg/dl. Human thrombin (Baxter Healthcare Inc.;
Norfolk, UK) was used to catalyze fibrin polymerization. ASCs
were resuspended in 80 ml of the fibrinogen solution and 20 ml of
thrombin (250 UI/ml) was added to the syringe containing the cell
suspension a few seconds before myocardium injection. This
combination allowed for a suitable window of time (20 seconds) to
perform the myocardial injection prior to polymerization.
Collagen was isolated from rat tail tendons using the method
described by Habermehl et al. [37] with slight modifications.
Briefly, tail tendons were extracted under sterile conditions, rinsed
in deionized water and dissolved in 1% acetic acid (v/v). After
72 hours at 4uC, the solution was centrifuged at 30,0006g for
2 hours and the supernatant collected and stored at the same
temperature. Before in vitro and in vivo assays, the acid soluble
collagen solution was neutralized by mixing with 0.1 N sterile
solution of NaOH in water, and the final concentration was
adjusted to 3 mg/ml. The physiological pH at 37uC resulted in
jellification of collagen.
Cellular viability assay
ASC proliferation/viability was evaluated by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say for up to 4 days, based on the reduction of tetrazolium salt to
formazan crystals by living cells, as previously described [38].
Approximately 170 ml of MTT solution (5 mg/ml) was added to
each well. After two hours, cell morphology was analyzed by
inverted optical microscopy, and formazan salts were dissolved
with 10% SDS/0.01 N HCl. The mixture was incubated for
18 hours, and optical density (O.D.) measurements were per-
formed at 540 nm (ELX 800, Biotek).
ASC radiolabeling
CeretecH lyophilized kit (GE Healthcare; Cardiff, UK) was
reconstituted in 2 ml of 0.9% NaCl solution containing 1.48 GBq
(40 mCi) of sodium pertecnetate (IPEN-CNEN, Brazil). Radio-
chemical purity of the labeled product [technetium 99m–
hexamethylpropylene amine oxime (99mTc-HMPAO)] was deter-
mined by ethyl acetate/saline extraction procedure. ASCs were
labeled with 99mTc-HMPAO, as previously described for unfrac-
tionated BMCs [32]. Briefly, the suspension of ASCs was
centrifuged and the pellet was resuspended in 1 ml of 99mTc-
HMPAO solution and incubated for 15 minutes at 37uC. Plasma
was added to interrupt cell tagging and the suspension was
centrifuged at 4666g for 10 minutes. The supernatant was
discarded and the pellet resuspended in PBS. The centrifugation
and suspension procedure was repeated. Labeling efficiency,
calculated as the ratio of the activity in 99mTc-labeled ASCs to
the total radioactivity was 15%.
To evaluate ASC labeling stability and nonspecific retention of
free tracer into the biopolymer mesh, 16105 radiolabeled cells
were plated, incubated for 24 hours and separated from the
culture medium by centrifugation. Radioactivity was measured in
the pellet and supernatant, and expressed as the ratio of the
radioactivity in each fraction to the total radioactivity (radioactiv-
ity in cells plus in supernatant). Similar to previously published for
BMCs [32], only 30.160.3% of the radioactivity initially
incorporated by the ASCs remained within the cells 24 hours
after labeling. Since no significant deterioration of cell viability was
detected by the trypan blue dye exclusion test, in the present study,
radioactivity values were also corrected according to the rate of
99mTc leakage from ASCs in vitro (fixed at 30.0%) assuming an
equivalent rate of leakage in vivo.
ASC Therapy for Cardiac Repair
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Cell transplantation
Twenty-four hours after the MI, animals were subjected to a
second surgical procedure for a single transepicardial injection of
16106 ASCs suspended in 100 ml of one of the following vehicles:
serum-free DMEM culture medium (group ASC/M), fibrin (group
ASC/F) or collagen (group ASC/C). Controls receiving same
volumes of cell-free media (group M), fibrin (group F) or collagen
(group C) were also injected. All injections were performed within
the infarct border zone of the anterior left ventricular free wall using
a 30-gauge needle. False-infarcted animals (Sham group) were used
as normal animals for cardiac morphometry and function. Please
note that there was no attempt to select animals with comparable
MI areas prior cell transplantation (24 hours after coronary
ligation), so only animals with comparable MIs, four weeks later,
were analyzed for the different phenotypes. This precludes the
assessment of the treatments on the MI size, but allows a careful
estimate of the interventions on the different phenotypes in animals
with comparable MI areas. The 24 hour time-point was selected to
avoid immediate post-MI acute inflammatory phase that may
contribute to increase cell death and decrease cell engrafting and
due to the fact that cardiac cell retention appears to be similar
within the 24–72 hour post-MI[32].
Nuclear radiometry of harvested organs
Animals that received radiolabeled ASCs were euthanized
24 hours after cell transplantation and heart, lungs, liver, spleen,
kidneys, femur and a sample of blood (approximately 3 ml) were
harvested and weighed. Radioactivity levels of the whole isolated
organs were determined in a gamma counter (Automatic Gamma
Counter 1480 – Perkin Elmer; Shelton CT, USA). Radioactivity
values of blood and bones were estimated from the amount of
radioactivity in samples of these tissues, considering them as 7%
and 10%, respectively, of the mass of the entire animal [39]. The
results were expressed as a percentage of total injected radioac-
tivity after correction for radioactive decay.
Morphometric analyses and capillary density
determination
At the end of experimental procedures, hearts were quickly
removed and fixed in 10% formalin for 24 hours, embedded in
paraffin, and histologically sectioned (5 mm). Samples were
mounted onto slides and stained with Picrossirius Red for
measurement of the following morphometric parameters: (i) average
scar size and (ii) thickness, (iii) left ventricular wall perimeter, (iv)
average thickness of the interventricular septum and (v) the
percentage of its area occupied by interstitial collagen. Capillary
densities were evaluated at the infarct border zones of samples
stained with Periodic Acid of Schiff (PAS), and expressed as the
mean number of capillaries in the area of the fields (mm2) at 4006
magnification. All procedures were performed in samples obtained
from middle and apical transversal segments of the heart and results
were expressed as the mean of the values from both segments.
Images were obtained by an image acquisition software system (NIS
- Elements AR 2.30) and measurements were determined by
ImageToolH software (UTHSCSA). Infarct size was estimated as
the percentage of left ventricular perimeter containing scar tissue.
All measurements were performed by two independent
investigators blinded to the experimental treatments.
Global cardiac function by direct hemodynamic
evaluation
Thirty days after MI, invasive hemodynamic studies were
performed on a heated rodent operating table (37uC) under
adjusted anesthesia (urethane 1.2 g/kg), and oxygen-enriched
mechanic ventilation. Left femoral vein was accessed to supple-
ment anesthesia, drugs or saline. Bilateral vagotomy was
performed to prevent changes in heart rate values induced by
the baroreflex. A Millar micro manometer (MikroTipTM 2F,
Millar Instruments Inc., Houston, TX, USA) was inserted from
the right carotid artery to the LV cavity to access intraventricular
pressure. A blood flow ultrasound probe (Transonic Systems Inc.
NY, USA) was positioned on the ascending aorta to access stroke
volume (SV) (excluding coronary flow) through right thoracotomy.
Data were acquired by the software Acknowledge (Biopac
Systems, CA, USA) to measure systolic (LVSP) and end-diastolic
left ventricle pressures (LVEDP), heart rate (HR), cardiac output
(CO) and SV. Stroke work (SW) was estimated offline as a product
of SV6developed pressure (LVSP – LVEDP)6constant 0.0136.
Hemodynamic parameters were determined under basal
conditions and during a sudden pressure-overload with a
vasoconstrictive phenylephrine (PHE) bolus injection (25–75 mg/
kg body weight) into the left femoral vein [40]. PHE doses were
adjusted for individual animals to produce comparable elevations
in blood pressure (60% to 80% greater than baseline).
Statistical analysis
Results are expressed as mean 6 standard error of the mean
(SEM). One- or two-way analysis of variance (ANOVA) with
Turkey’s post-hoc test, or unpaired Student’s t test was utilized to
compare groups, when appropriate. All statistical analyses were
performed using GraphPad Prism 4.0 (GraphPad Softwares Inc.,
CA, USA). P values#0.05 were considered significant.
Results
Viability of ASCs cultured in biopolymers
To assess differential effects of biopolymers on cell survival, we
investigated the viability of ASCs seeded in vitro in three-dimensional
(3D) scaffolds of fibrin and collagen for up to 4 days using the MTT
assay. The O.D. used as an index of cell density at 24 hours post
seeding was significantly higher in ASCs seeded in collagen
compared to fibrin (ASC/C 0.129560.861023 vs. ASC/F
0.099561.5761023; P,0.05) denoting higher viability (figure 1A).
Optical density values gradually decreased in ASCs cultured in both
biopolymers as expected in cells seeded in scaffolds, as a
consequence of changes in mechanical properties which in turn
affects cell growth [41]. Figure 1B shows representative micropho-
tographs of MTT stained plates across time.
ASC cardiac retention and biodistribution
To determine the biopolymer with the best profile in terms of
cardiac cell retention, radiolabeled ASCs were injected into the
infarct border zone 24 hours post-infarction using either fibrin
(group ASC/F), collagen (group ASC/C) or culture medium
(group ASC/M) as vehicle, and radioactivity was assessed in
several tissues 24 hours after injection. As expected, both
biopolymers significantly increased ASC cardiac cell retention
compared to culture medium (figure 2A). The ASC/C group
showed the highest radioactivity retention (26.862.4%), which
nearly doubled the retention observed for the ASC/F group
(13.761.9%, P,0.05 vs. ASC/C) and five-folded the value
observed for ASC/M (4.8460.7% vs. ASC/C, P,0.05). To
examine the possibility that the tracer that leaked from the cells
was nonspecifically retained in the biopolymer mesh, radiolabeled
ASCs were incubated either into biopolymer scaffolds (ASC/C
and ASC/F) or as adherent cultures (ASC/M) for 24 hours and
radioactivity was measured in both the cell and the supernatant
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fractions. The amount of radioactivity in the cell fraction was
highly similar for all groups (30.663.4; 29.564.5 and 30.262.2%
for cells cultured in M, F and C respectively; P.0.05), indicating
that it is unlikely tracer leaked from the cells, remained bound to
the biopolymers, and interfered with the results obtained.
Interestingly, the distribution of radioactivity among several tissues
24 hours after injection showed that most labeled cells did not remain
in the heart. An inverse relationship was observed between cardiac
ASC retention and lung retention (figure 2B). These results suggest
that ASCs which are washed out from the myocardium through the
lymphatic vessels and veins from the left ventricle (LV) may ultimately
be delivered into lung tissue. High radioactivity levels were also
detected in liver and kidney tissues, and markedly lower values were
noted in spleen, bones and adipose tissue.
Figure 1. Cell viability on 3D biopolymer scaffolds. (A) Variation of optical density (O.D.) with time in culture. The O.D. at 540 nm indicates cell
viability. *, P,0.05 vs. ASC/F. (B) Microphotographs of representative cultures after MTT stain. Magnification 406. ASC/F, cells cultured in fibrin (n = 6);
ASC/C, cells cultured in collagen (n = 6).
doi:10.1371/journal.pone.0012077.g001
Figure 2. Effects of injectable biopolymers on ASC cardiac retention. (A) Cardiac retention of ASCs 24 hours after intramyocardial injection
using either culture medium (ASC/M, n = 12), fibrin (ASC/F, n = 13) or collagen (ASC/C, n = 16). (B) Distribution of radioactivity in different organs
according to the vehicle used to administer the radiolabeled ASCs into the myocardium. Data are expressed as percentage means (6SEM). A.T.,
adipose tissue. *, P,0.05 vs. ASC/M; #, P,0.05 vs. ASC/F.
doi:10.1371/journal.pone.0012077.g002
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Therapy effects on heart morphometry
To assess whether the enhanced cardiac retention of ASCs
influenced the deterioration normally observed in the left ventricle,
morphometric parameters indicative of ventricular remodeling
were analyzed in the experimental groups 4 weeks after MI
(shown in table 1). As depicted in figure 3A, no differences in
infarct size among groups were observed (33.461.8; 36.362.9;
36.661.5; 32.761.2; 34.361.9; 33.060.7 and 34.061.4% for
NT, M, F, C, ASC/M, ASC/F and ASC/C respectively; P.0.05).
This finding can be explained by the pre-established selection
criteria in which only animals with infarcts ranging from 30 to
40% of the LV perimeter at the end of the protocol were included
in the analyses. Indeed, ligation of the left anterior descending
coronary artery results in large variation in MI size. For this
reason, animals with comparable MI dimensions may be selected
by echocardiography prior to treatment randomization or,
alternatively, animal randomization may initially occur followed
by selection of animals with comparable MI dimensions at the end
of the protocol. Although results cannot be used to evaluate MI
size in the case of the latter example, results can shed light on the
influence of the treatments in cardiac structure and function at a
period of 4 weeks post-MI.
Figure 3. Cardiac morphometry 4 weeks after treatment. (A) Myocardial infarct size estimated as the percentage of left ventricle perimeter
occupied by scar. (B) Left ventricle perimeter expressed in millimeters. (C) Interventricular septum thickness in millimeters. (D) Fibrosis in spare
myocardium, expressed as percentage of septum area occupied by interstitial collagen. (E) Scar thickness in millimeters. (F) Capillary density, as the
mean of number of capillaries per area (mm2; magnification 4006). Note that Sham capillary density averages 1793 capillaries/field as shown in the
traced line. MI, myocardial infarct size; LV, left ventricle; IC, interstitial collagen; Sham, (n = 7); NT, non-treated (n = 8); M, culture medium (n = 5); F,
fibrin (n = 6); C, collagen (n = 6); ASC/M, ASCs in culture medium (n= 6); ASC/F, ASCs in fibrin (n = 7); ASC/C, ASCs in collagen (n = 6). *, P,0.05 vs.
Sham; #, P,0.05 vs. NT; +, P,0.05 vs. respective vehicle control.
doi:10.1371/journal.pone.0012077.g003
Table 1. Experimental groups.
Group MI Content n
Sham 2 - 7
NT + - 8
M + Medium 5
F + Fibrin 6
C + Collagen 6
ASC/M + 16106 ASCs+medium 6
ASC/F + 16106 ASCs+fibrin 7
ASC/C + 16106 ASCs+collagen 6
MI, myocardial infarction; n, number of animals in each group; Sham; false
infarcted; NT, non-treated; M, culture medium; F, fibrin; C, collagen; ASCs,
adipose tissue-derived stem cells; ASC/M, ASCs in culture medium; ASC/F, ASCs
in fibrin; ASC/C, ASCs in collagen.
doi:10.1371/journal.pone.0012077.t001
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In groups NT, M, F, C and ASC/M, the perimeter of the LV
was significantly increased compared to the Sham group
(33.560.2; 34.061.1; 33.160.8; 32.460.5 and 31.560.6 mm
for NT, M, F, C and ASC/M respectively vs. 27.460.2 mm for
Sham; P,0.05) as a consequence of the negative remodeling effect
of the infarct (figure 3B). Conversely, in groups ASC/F and ASC/
C, LV perimeter was preserved showing an overall smaller
ventricle size (29.563.3 mm and 29.761.0 mm, respectively) and
the LV perimeter values for group ASC/F were lower than that
observed for the NT group (P,0.05).
Increase in septum thickness, an indicator of cardiac hypertro-
phy, remained unchanged in the ASC-treated groups. A tendency
for increased septum thickness was noted in the control groups
following the MI, but reached significance in the NT group
compared to Sham group (2.060.1 vs. 1.460.0 mm for NT vs.
Sham; P,0.05) (figure 3C).
Fibrosis in the spare myocardium, measured as the percentage
of the septum area occupied by interstitial collagen, was
significantly higher in NT, M, F, C and ASC/M groups when
compared to Sham (2.960.1; 2.760.2; 2.360.1; 2.460.2;
2.060.1% of septum area for NT, M, F, C and ASC/M
respectively vs. 1.260.1% for Sham; P,0.05) (figure 3D).
Moreover, the groups that received ASCs, associated or not with
biopolymers, showed lower percentages of interstitial collagen than
the NT group (2.060.1; 1.960.1; and 1.860.1% for ASC/M,
ASC/F and ASC/C respectively vs. 2.960.1% for NT; P,0.05).
Similarly, the scars tended to be thicker in ASC-treated (figure 3E),
but reached significance only in the ASC/C compared to NT
group (1.260.0 mm for ASC/C vs. 0.760.0 mm for NT;
P,0.05).
The capillary density in the infarct border zone tended to be
higher in the cell-treated groups, but reached significance only in
the ASC/F compared to group NT (11396194.3 vs. 500658.9
capillaries/mm2 for ASC/F and NT respectively; P,0.05)
(figure 3F and Figure S1). It is important to notice that four
weeks after cell transplantation, there was no evidence of lasting
polymers in the areas of cardiac tissue where labeled injected cells
were present (Figure S2 and Methods S1).
Therapy effects on cardiac function
Cardiac performance was measured by direct hemodynamic
assessment carried out under both basal conditions and conditions
associated with a pharmacologic challenge upon injection of a
potent vasoconstrictor, phenylephrine. Under basal conditions,
indices of ventricular function in infarcted animals were worse
than Sham animals (table 2). While LVSP diminished in group M,
LVEDP increased in groups NT and C.
Upon phenylephrine injection, the cardiovascular phenotypic
changes became much more evident, underscoring the improve-
ment in the ASCs treated groups (figure 4). The degree of change
on SV (amount of blood pumped from the ventricle in each cycle)
in response to pressure overload was better preserved in the ASC
groups compared to the NT group, and significantly different than
their respective vehicle controls (233.062.9; 227.061.7 and
216.263.6 vs. 253.762.5% for ASC/M, ASC/F and ASC/C vs.
NT; and vs. 260.663.0; 254.566.9 and 254.163.8% for M, F
and C; P,0.05) (figure 4A). The LVEDP values increased
significantly post-MI in NT, M, F and C groups, whereas all
ASC-treated groups exhibited pressure responses equivalent to the
Sham animals which were significantly lower than both NT and
their vehicle control groups (22.363.0; 20.262.9; 16.562.1;
17.362.6; 6.661.2; 4.560.9; 6.260.8 and 2.760.4 mmHg
increase compared to baseline values for NT, M, F, C, ASC/M,
ASC/F ASC/C and Sham respectively; P,0.05 for differences vs.
Sham and vs. NT, P,0.05 for ASC/M and ASC/F vs. respective
vehicle controls, and P,0.05 for ASC/C vs. C) (figure 4B). Finally,
stroke work, a global index of cardiac function that depends on
both pressure generation and ejection capability during each beat,
displayed comparable profile in ASC-treated and Sham groups,
with the exception of the ASC/M group which was injected in
absence of any biopolymer and showed a significant difference
from Sham (9.165.5; 25.762.1 and 38.062.8% change from
baseline, for ASC/M, ASC/F and ASC/C, respectively vs.
X6Y% for Sham; P,0.05 for ASC/M vs. Sham) (figure 4C). In
contrast, all control groups showed negative changes in work
generation in response to pharmacologic stress post-MI
(231.564.7%, 245.065.5, 227.5610, and 223.066.2% for
NT, M, F, and C, respectively. P,0.05 for all controls vs. Sham
and ASC treated groups) (figure 4C).
Correlation between ASC cardiac retention and cardiac
performance
To obtain further evidence that ASC cardiac retention
(determined as the percentage of total injected radioactivity
remaining in the heart 24 hours post-injection) and improvement
of cardiac performance post-MI (determined as the response to
sudden afterload stress assessed 4 weeks after injection) may be
linked, we performed a linear regression analysis. A significant
Table 2. Hemodynamic variables under basal conditions.
Sham NT M F C ASC/M ASC/F ASC/C
LVSP (mm Hg) 119.664.6 116.664.1 101.461.9 * 109.763.4 115.563.2 112.862.5 110.962.1 114.563.7
LVEDP (mm Hg) 4.761.2 13.061.5* 11.661.1 10.360.8 11.863.2 * 8.560.4 9.061.0 7.661.0
HR (bpm) 356631 328612 365616 396612 374620 378611 364611 358616
+dP/dt (mm Hg/s) 99916464 71246285* 60196366* 72306438 * 80726415*{ 85636474{ 79356267* 89066557{
2dP/dt (mm Hg/s) 267416430 251336178* 244496148* 254766247 256916354 258726159 254516218 262406469
CI (ml/kg/min) 190614 20166.9 183618 15464.7 201619 160618 19168.7 170619
SVI (ml/kg/beat) 0.49060.052 0.59660.051 0.49860.057 0.39260.014 0.59860.067 0.42460.045 0.41060.049 0.48560.066
SW (g?m/beat) 0.66460.116 0.92860.074 0.61460.072 0.53160.028 0.80060.081 0.60160.063 0.65960.089 0.69860.091
LVSP, left ventricular systolic; LVEDP, left ventricular end-diastolic pressures; HR, heart rate; CI, cardiac ejection index; SV, stroke volume index; SW, stroke work index.
Sham, false operated; NT, non-treated; M, culture medium; F, fibrin; C, collagen; ASC/M, ASCs in culture medium; ASC/F, ASCs in fibrin; ASC/C, ASCs in collagen.
*P,0.05 vs. Sham.
{P,0.05 vs. M. One-way ANOVA followed by Tukey’s post-hoc test.
doi:10.1371/journal.pone.0012077.t002
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correlation between ASC cardiac retention and both main-
tenance of stroke volume (r2 = 0.9968; P,0.05) (figure 5A) and
increment of stroke work generation during the phenylephrine-
induced afterload stress (r2 = 0.9638; P,0.05) (figure 5B) was
demonstrated.
Discussion
In the present study, we provided evidence that intramyocardial
injection of ASCs 24 hours post-MI, delivered with culture
medium, fibrin or collagen, significantly preserves left ventricular
function, as assessed by direct hemodynamic evaluation. A
correlation between cell retention capacity and preservation of
stroke volume and capacity to generate cardiac work in response
to pharmacologic stress was shown suggesting that these beneficial
effects are proportional to cell number retention (figure 5). Unlike
previously published studies [29,42], under the present experi-
mental conditions, the biopolymers per se did not show any effect
on cardiac morphometry or function. Instead, the main effect of
the biopolymers appeared to propagate an increase in local
entrapment and/or survival of the transplanted cells.
Our data confirmed recent reports showing that transplantation
of ASCs can favorably affect cardiac function after both acute and
chronic infarction [18,19,20,21]. Here, however, we further
extended previous observations in three significant ways. First,
we tested the therapeutic potential of ASC in combination with
two important biopolymers for cell transplantation and tissue
engineering, fibrin and collagen. These injectable and biodegrad-
able scaffolds were shown here, as well as in previous studies
[29,30,31,32,42], to increase engraftment of transplanted cells and
to preserve cardiac function after infarction. Second, we assessed
the cardiac retention of ASCs 24 hours after injection with
different delivery vehicles. This approach allowed for the
evaluation of the cell retention capacity of the tested biomaterials,
to correlate degree of ASC retention with degree of heart function
preservation, and to determine the main organs that cells spread.
Third, we evaluated ventricular function by performing stringent
invasive hemodynamic tests that allowed for direct measurements
of ventricular pressure and aortic blood flow.
Interestingly, the favorable outcomes on cardiac function that
we observed in this study were not manifested primarily by
changes in resting or basal hemodynamic parameters but rather,
in the altered cardiac response to stimuli such as sudden afterload
stress induced by phenylephrine. A possible explanation for this is
the rigorous inclusion criterion of animals with MI size of a limited
range. While different infarct sizes may or may not affect cardiac
Figure 4. Cardiac response to afterload stress. Bars represent repercussions induced by phenylephrine injection, expressed as % of change
from baseline (except for LVEDP, expressed as mm Hg elevation over baseline), on the stroke volume, LV end-diastolic pressure (LVEDP) and stroke
work of Sham (n= 7), NT (n = 8), M (n = 5), F (n = 6), C (n = 6), ASC/M (n= 5), ASC/F (n = 7), and ASC/C (n = 6) groups. Positive or negative values resulted
from increase or decrease on the evaluated parameter, respectively. *, P,0.05 vs. Sham; #, P,0.05 vs. NT; +, P,0.05 vs. respective vehicle control.
doi:10.1371/journal.pone.0012077.g004
Figure 5. Dose-dependent effects of ASCs in heart function. Relationship between cell retention in the host myocardium (radioactivity of
labeled ASC assessed 24 hours after injection) and cardiac performance (response to sudden afterload stress in terms of heart ejection (A) and stroke
work (B) assessed 4 weeks after injection) of the infarcted hearts injected with ASC in culture medium (ASC/M), fibrin (ASC/F) or collagen (ASC/C). For
radioactivity assay, samples were ASC/M=12, ASC/F = 13, and ASC/C= 16; and for hemodynamic study, samples were ASC/M= 6, ASC/F = 7, and ASC/
C= 6.
doi:10.1371/journal.pone.0012077.g005
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function receiving cell therapy [43], in the present study, the
selection criterion precluded assessment of the different treatments
on infarct expansion. This approach revealed an important
influence of ASC treatment on cardiac performance in MIs of
comparable sizes four weeks after the insult. A direct relationship
between the percentage of cardiac cells retained and the degree of
cardiac function preservation post-MI was demonstrated, suggest-
ing a dose effect for ASCs. Similar beneficial effects in cardiac
performance post-MI were observed when we injected bone
marrow cells (BMCs); however, no dose effect was detected for
BMCs under the same conditions tested here [32,44].
Although acute cardiac retention of ASC is markedly low, our
data demonstrate that it can be significantly improved when cells
are delivered in association with fibrin and collagen. For example,
the intramyocardial co-injection of radiolabeled ASCs and
collagen increased the amount of radioactivity five-fold in the
infarcted heart at 24 hours following injection. In addition, we
showed that the increased radioactivity retention observed when
ASCs were delivered with fibrin and collagen were unlikely due to
nonspecific trapping of free radiotracer in the biopolymers mesh,
further confirming our previous results [32]. As expected, the
nuclear radiometry of the harvested organs revealed a broad
biodistribution of radiolabeled ASCs, with high radioactivity
values detected in liver, kidney and lung tissues, and markedly
lower values in spleen and bone tissues. In addition, for each
delivery vehicle employed, we observed an inverse relationship
between radioactivity accumulation in the heart and lungs. The
noticeable ASC entrapment into the pulmonary circulation
suggests that, excluding cell death, the major mechanism of cell
loss is due to the washout from the myocardium through
lymphatic vessels and veins of the left ventricular wall and may
be associated with the time delay for the liquid carriers to fully
polymerize. It was noteworthy that the biopolymers tested in this
study do not compromise the viability of ASCs in vitro and do not
elicit cardiac arrhythmias in vivo (data not shown).
The mechanisms by which ASCs may exert their beneficial
effects deserve to be further explored; however, this is beyond the
scope of this study. Based upon the observed improvements in
terms of fibrosis attenuation and the overall preservation of left
ventricular shape and size, which in turn improve function
[45,46,47], we speculate that one of the underlying mechanisms
may be the activation and/or potentiation of endogenous
myocardial healing programs by paracrine means. This idea is
supported by data reported in previous studies [18,48,49]. In
addition, our data also revealed both an increase in capillary
density among the ASC-treated groups and a tendency for an
increase in scar wall thickness. While the former can have
beneficial effects on cell preservation and cardiac function, the
latter may provide mechanical support for the infarcted area
improving overall cardiac function.
Taken together, the main finding of the present study is that
intramyocardial injection of ASCs mitigates the negative cardiac
remodeling and preserves ventricular function post myocardial
infarction. In addition, we demonstrated that the beneficial effects
on cardiac function can be further enhanced by administrating
cells along with injectable biopolymers. Consequently, the results
reported here may have important implications for the design of
future cell therapy strategies for cardiac repair.
Supporting Information
Figure S1 PAS staining for capillary quantification. Arrowhead
indicates a single capillary in the heart sections from different
groups. NT, non-treated; M, culture medium; F, fibrin; C,
collagen; ASC/M, ASCs in culture medium; ASC/F, ASCs in
fibrin; ASC/C, ASCs in collagen. Magnification 4006.
Found at: doi:10.1371/journal.pone.0012077.s001 (2.04 MB TIF)
Figure S2 Immunodetection of GFP+ASCs four weeks after
transplantation. Upper panel (A, B and C): immunohistochemis-
try. Bottom panel (D, E and F): immunofluorescence at infarction
border zone. Arrowheads show the GFP+ASCs. Magnification
4006.
Found at: doi:10.1371/journal.pone.0012077.s002 (2.04 MB TIF)
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Found at: doi:10.1371/journal.pone.0012077.s003 (0.02 MB
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